Seems to be a busy season for press releases regarding IBS medications (see, "More Delays for Xifaxan" and "Linaclotide Advances in Quest for FDA Approval"). I am very encouraged by this, as pharmaceuticals eager to cash in on the IBS market are putting effort into coming up with improved treatment options. The most recent press release has to do with a medication currently titled "LX1031", being evaluated for its effectiveness in the treatment of Non-Constipation IBS.
I first wrote about LX1031 following positive results of a Phase II clinical trial, (see, "LX1031: Up-and-Coming IBS Medicine"). LX1031 is a medication designed to inhibit tryptophan hydroxylase (TPH) with the effect of reducing the amount of serotonin produced in the lining of the intestines. The current news has to do with the results of a Phase II trial published in the journal, Gastroenterology. According to the study abstract, 155 patients with non-constipating IBS were given LX1031, at two different dosage levels, for a period of 28 days. Patients given the higher dose of the medicine experienced significant relief of IBS pain, as compared to those given a placebo at the end of the first week. Improvement continued over the next few weeks, but not at a level of statistical significance. The medication did produce significant improvement in "stool consistency" at various times throughout the study. Finally, a reduction was seen in a biomarker for TPH and this was associated with symptom improvement. The medication was well-tolerated by the study participants.
Although these results can be considered positive, Lexicon, the manufacturer of the medication, has turned its efforts toward the development of LX1033, a similar formulation, due to the fact that it shows results at a lower and less frequent dosage then LX1031. For more information on LX1033, see "Potential IBS-D Drug: LX1033". I take it as a good sign that the manufacturers are looking to refine the medicine. Let's hope that their efforts pay off in terms of offering a safe and effective treatment option for IBS-D.
Brown, P., et.al. "The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome" Gastroenterology 2011 141:507-516.
"Lexicon Announces Publication of Results from the Phase 2 Trial of LX1031 in Patients with Irritable Bowel Syndrome in Journal of Gastroenterology" Lexicon Pharmaceuticals Press Release August 10, 2011.
|| Facebook | Twitter | Newsletter Signup | Forum ||